Drug Landscape ›
Lactobacillus Plantarum 299v ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 11
Most-reported reactions
Bone Marrow Transplant — 2 reports (18.18%) Asthenia — 1 report (9.09%) Cytomegalovirus Infection Reactivation — 1 report (9.09%) Diarrhoea — 1 report (9.09%) Eye Discharge — 1 report (9.09%) Graft Versus Host Disease — 1 report (9.09%) Hypersomnia — 1 report (9.09%) Hypophagia — 1 report (9.09%) Nausea — 1 report (9.09%) Rash — 1 report (9.09%)
Source database →
Lactobacillus Plantarum 299v in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Lactobacillus Plantarum 299v approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Lactobacillus Plantarum 299v in United States?
Medical University of Bialystok is the originator. The local marketing authorisation holder may differ — check the official source linked above.